scholarly journals Effects of recombinant human erythropoietin (SNB-5001) on renal anemic rats induced by drugs.

1991 ◽  
Vol 98 (2) ◽  
pp. 151-160
Author(s):  
Hiroaki MASUNAGA ◽  
Reiko TAKAHIRA ◽  
Tadanori SAWAI
Keyword(s):  
Recombinant Human Erythropoietin ◽  
Human Erythropoietin

Correlation Between Recombinant Human Erythropoietin Dose and Inflammatory Status in Dialysed Patients

2017 ◽  
Vol 68 (2) ◽  
pp. 354-357 ◽  
Author(s):  
Andrei Niculae ◽  
Cristiana David ◽  
Razvan Florin Ion Dragomirescu ◽  
Ileana Peride ◽  
Flavia Liliana Turcu ◽  
...  
Keyword(s):  
Adverse Effects ◽  
Recombinant Human Erythropoietin ◽  
Best Practice ◽  
Daily Practice ◽  
Therapeutic Benefit ◽  
Chronic Dialysis ◽  
Dialysis Patients ◽  
Protein Levels ◽  
Human Erythropoietin ◽  
Inflammatory Status

Once recombinant human erythropoietin (r-HuEPO) was introduced in daily practice, huge steps were made in combating the adverse effects induced by anemia in chronic kidney disease population. Still, r-HuEPO resistance and the doses ensuring the maximum therapeutic benefit remain matters of debate. The aim of our study was to assess the correlation between the presence and the degree of inflammation and the r-HuEPO requirements in chronic dialysis patients. We conducted a 2 years prospective study on 146 patients undergoing chronic dialysis treated with r-HuEPO. Based on their average CRP (C-reactive protein) levels, obtained from repeated samplings at 3 months interval, 3 groups were formed; we noted in each group the average values of r-HuEPO prescribed to achieve the optimum hemoglobin levels according to the dialysis best practice guidelines and all the adverse effects of the therapy. A direct correlation was observed between CRP levels and r-HuEPO requirements in the first 2 groups of patients (CRP under 6 mg/L and CRP values 6-20 mg/L), with significant increase in r-HuEPO doses between groups (p [ 0.001); the third group, CRP values over 20 mg/dL, showed a minor, insignificant increase in average r-HuEPO doses compared to mild inflammation group (p = 0.199) and more adverse effects of the therapy (p [ 0.05). Inflammation is an important determinant of anemia in chronic dialysis patients and can induce an increase in the doses of r-HuEPO. However, prescribing excessive r-HuEPO doses is not the answer in severe inflammatory status, due to lack of response and possible adverse effects.

Biochemical and Biological Quality Control of Two Recombinant Human Erythropoietin Biosimilar Products

2017 ◽  
Vol 13 (6) ◽  
Author(s):  
Rym Hassiki ◽  
Jamila Behi ◽  
Nadia Ben Said ◽  
Lassaad Boujbel ◽  
Balkiss Bouhaouala-Zahar
Keyword(s):  
Quality Control ◽  
Recombinant Human Erythropoietin ◽  
Biological Quality ◽  
Human Erythropoietin

scholarly journals Effect of Recombinant Human Erythropoietin on Nutritional Status and Plasma Lipids in Uremic Patients

Nephron ◽  
1992 ◽  
Vol 60 (2) ◽  
pp. 249-249 ◽  
Author(s):  
B. Viron ◽  
R. Donsimoni ◽  
C. Michel ◽  
R. Al Khayat ◽  
F. Mignon
Keyword(s):  
Nutritional Status ◽  
Recombinant Human Erythropoietin ◽  
Plasma Lipids ◽  
Human Erythropoietin ◽  
Uremic Patients

scholarly journals Recombinant Human erythropoietin reduces viability of MCF-7 breast cancer cells from 3D culture without caspase activation

2021 ◽  
Vol 28 (4) ◽  
pp. 2549-2557
Author(s):  
Hareth Y. ShujaaEdin ◽  
Nagi A. AL-Haj ◽  
Abdullah Rasedee ◽  
Noorjahan Banu Alitheen ◽  
Arifah Abdul Kadir ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Cells ◽  
Recombinant Human Erythropoietin ◽  
Breast Cancer Cells ◽  
3D Culture ◽  
Caspase Activation ◽  
Human Erythropoietin ◽  
Mcf 7

Haemodialysis – Related Porphyria Cutanea Tarda and Treatment by Recombinant Human Erythropoietin

Nephron ◽  
1992 ◽  
Vol 60 (4) ◽  
pp. 428-431 ◽  
Author(s):  
M. Yaqoob ◽  
J. Smyth ◽  
R. Ahmad ◽  
P. McClelland ◽  
I. Fahal ◽  
...  
Keyword(s):  
Recombinant Human Erythropoietin ◽  
Porphyria Cutanea Tarda ◽  
Human Erythropoietin
Sign in / Sign up

Export Citation Format

Share Document